Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Herpes Zoster (Shingles) Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Herpes Zoster (Shingles) Overview | 8 | 1 |
| Herpes Zoster (Shingles) Therapeutics under Development by Companies | 9 | 1 |
| Herpes Zoster (Shingles) Pipeline Products Glance | 10 | 4 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Unknown Stage Products | 13 | 1 |
| Herpes Zoster (Shingles) Products under Development by Companies | 14 | 1 |
| Herpes Zoster (Shingles) Companies Involved in Therapeutics Development | 15 | 14 |
| Astellas Pharma Inc. | 15 | 1 |
| Beijing Minhai Biotechnology Co., Ltd | 16 | 1 |
| ContraVir Pharmaceuticals, Inc. | 17 | 1 |
| Epiphany Biosciences, Inc. | 18 | 1 |
| Foamix Pharmaceuticals Ltd. | 19 | 1 |
| GeneOne Life Science, Inc. | 20 | 1 |
| GlaxoSmithKline Plc | 21 | 1 |
| Merck &Co., Inc. | 22 | 1 |
| N &N Pharmaceuticals Inc. | 23 | 1 |
| NAL Pharmaceuticals Ltd. | 24 | 1 |
| NanoViricides, Inc. | 25 | 1 |
| ReceptoPharm, Inc. | 26 | 1 |
| TSRL, Inc. | 27 | 1 |
| XBiotech Inc | 28 | 1 |
| Herpes Zoster (Shingles) Therapeutics Assessment | 29 | 9 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 23 |
| acyclovir Drug Profile | 38 | 1 |
| amenamevir Drug Profile | 39 | 1 |
| FV-100 Drug Profile | 40 | 4 |
| GLS-5100 Drug Profile | 44 | 1 |
| GSK-1437173A Drug Profile | 45 | 3 |
| herpes zoster vaccine Drug Profile | 48 | 1 |
| Monoclonal Antibody for Shingles Drug Profile | 49 | 1 |
| NAL-3221 Drug Profile | 50 | 1 |
| NAL-3223 Drug Profile | 51 | 1 |
| NN-001 Drug Profile | 52 | 1 |
| RPI-78M Drug Profile | 53 | 2 |
| Small Molecule for Shingles Drug Profile | 55 | 1 |
| TSR-087 Drug Profile | 56 | 1 |
| V-212 Drug Profile | 57 | 2 |
| valomaciclovir stearate Drug Profile | 59 | 2 |
| Herpes Zoster (Shingles) Dormant Projects | 61 | 1 |
| Herpes Zoster (Shingles) Discontinued Products | 62 | 1 |
| Herpes Zoster (Shingles) Product Development Milestones | 63 | 11 |
| Featured News &Press Releases | 63 | 1 |
| Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM | 63 | 1 |
| Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles | 64 | 1 |
| Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug | 65 | 1 |
| Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study | 65 | 1 |
| Oct 27, 2015: GSK s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over | 66 | 1 |
| Sep 08, 2015: Clinical trial for Cardiff s shingles treatment | 67 | 1 |
| Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain | 67 | 1 |
| Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial | 68 | 1 |
| Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied | 68 | 1 |
| Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN | 69 | 1 |
| Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint | 70 | 1 |
| Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant | 71 | 1 |
| Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles | 71 | 1 |
| Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles | 72 | 1 |
| Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older US Population, Cohort Study Finds | 72 | 2 |
| Appendix | 74 | 2 |
| Methodology | 74 | 1 |
| Coverage | 74 | 1 |
| Secondary Research | 74 | 1 |
| Primary Research | 74 | 1 |
| Expert Panel Validation | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 75 | 1 |